Osteoporosis drugs known as bisphosphonates may not protect women from breast cancer as had been thought, according to a new study.
The epidemiology and pathophysiology of cancer-associated bone disease was reviewed in a new paper published by an International Osteoporosis Foundation (IOF) Committee of Scientific Advisors Working Group.
A review of calcium and vitamin D supplementation trials revealed that current recommended doses are inadequate to prevent bone mineral density loss in women undergoing breast cancer therapy.
FDA-related news items of relevance from the month of June, 2013.
When patients with giant-cell tumor of the bone were treated with denosumab, which is a drug targeted against a protein that promotes bone destruction, the number of tumor giant cells decreased and new bone formation increased.
Calcium and/or vitamin D supplementation at commonly recommended doses does not prevent bone loss from androgen-deprivation therapy.
Denosumab better prevents skeletal complications, ups health-related QoL versus zoledronic acid.
A history of periodontitis may be associated with an increased risk of HPV-positive tumors in persons with head and neck squamous cell carcinoma.
Study finds loss evident in men treated with ADT for nonmetastatic, hormone-sensitive prostate cancer.
The risk of bone loss resulting from breast and prostate cancer treatment has been highlighted by researchers in Canada.
Sign Up for Free e-newsletters
- Real World Results May Not Mirror Clinical Study Outcomes in Multiple Myeloma
- Is Radioimmunotherapy a Path Forward for Melanoma?
- FDA Approves Mogamulizumab-kpkc for Rare Subtypes of Non-Hodgkin Lymphoma
- Handling Chemotherapy Premedications
- New PDL1 Inhibitors for Non-small Cell Lung Cancer: Focus on Pembrolizumab
- NCCIH HerbList App Launched to Provide Information on Herbal Products
- Metformin Use May Improve Survival Outcomes in Bladder Cancer
- Higher Vitamin D Levels Associated With Lower Breast Cancer Risk
- Nurse-Led Program Improves Health, Financial Outcomes in Outpatient Chemotherapy
- Seeking Reliable Information on Herbal Products
- Disparities Remain in Prevalence of Cancer Screening Tests
- Hope, Gratitude, and Spirituality: What They Mean to Cancer Patients
- FDA, EU Approvals Sought for Split Dose Regimen of Daratumumab for Multiple Myeloma
- 8 Hours of Bedrest May Be Ideal After Intrathecal Chemotherapy in Hematologic Cancers
- Combined Digital Screening Best for Detecting Breast Cancers
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|